Caris Life Sciences/$CAI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Caris Life Sciences
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
Ticker
$CAI
Sector
Primary listing
Employees
1,769
Headquarters
Website
CAI Metrics
BasicAdvanced
$8.9B
-
-$18.57
-
-
Price and volume
Market cap
$8.9B
52-week high
$42.50
52-week low
$25.40
Average daily volume
671K
Financial strength
Current ratio
9.241
Quick ratio
8.578
Long term debt to equity
90.963
Total debt to equity
92.51
Interest coverage (TTM)
-2.94%
Profitability
EBITDA (TTM)
-140.776
Gross margin (TTM)
53.86%
Net profit margin (TTM)
-52.27%
Operating margin (TTM)
-32.56%
Revenue per employee (TTM)
$300,000
Management effectiveness
Valuation
Price to revenue (TTM)
2.544
Price to book
19.6
Price to tangible book (TTM)
20.47
Price to free cash flow (TTM)
-9.659
Free cash flow yield (TTM)
-10.35%
Free cash flow per share (TTM)
-3.27
Growth
What the Analysts think about CAI
Analyst ratings (Buy, Hold, Sell) for Caris Life Sciences stock.
Bulls say / Bears say
Caris raised $494.1 million through its IPO by selling 23.5 million shares at $21 apiece, planning to use the capital to pay down debt and invest in operations to drive growth. (Reuters)
For 2024, Caris reported annual revenue of $412.3 million, representing 34.6% growth over $306.1 million in 2023, highlighting continued strong sales momentum. (WSJ)
The company has run more than 6.5 million tests on 849,000 clinical cases, collaborating with over 100 biopharma firms including Moderna and AbbVie, which shows significant market reach and broad industry support. (Reuters)
At its targeted $5.35 billion IPO valuation, Caris’s price-to-sales ratio of about 13 puts it at the high end among peers, demanding strong future growth to justify such a premium. (Reuters)
Caris faces intense competition in the precision oncology diagnostics field from established rivals like Guardant Health and Grail; maintaining market share will require clear clinical outcome advantages. (Reuters)
Healthcare IPOs account for only 5% of new listings in 2025, down from 70% for finance and tech, indicating ongoing sector challenges may weigh on investor interest despite Caris’s strong launch. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2025.
CAI Financial Performance
Revenues and expenses
CAI Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Caris Life Sciences stock?
Caris Life Sciences (CAI) has a market cap of $8.9B as of October 08, 2025.
What is the P/E ratio for Caris Life Sciences stock?
The price to earnings (P/E) ratio for Caris Life Sciences (CAI) stock is 0 as of October 08, 2025.
Does Caris Life Sciences stock pay dividends?
No, Caris Life Sciences (CAI) stock does not pay dividends to its shareholders as of October 08, 2025.
When is the next Caris Life Sciences dividend payment date?
Caris Life Sciences (CAI) stock does not pay dividends to its shareholders.
What is the beta indicator for Caris Life Sciences?
Caris Life Sciences (CAI) does not currently have a Beta indicator.